These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 33201337)
21. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. Donia M; Junker N; Ellebaek E; Andersen MH; Straten PT; Svane IM Scand J Immunol; 2012 Feb; 75(2):157-67. PubMed ID: 21955245 [TBL] [Abstract][Full Text] [Related]
22. Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial. Khammari A; Nguyen JM; Leccia MT; Guillot B; Saiagh S; Pandolfino MC; Knol AC; Quéreux G; Chiffolettau A; Labarrière N; Dréno B Cancer Immunol Immunother; 2020 Aug; 69(8):1663-1672. PubMed ID: 32306076 [TBL] [Abstract][Full Text] [Related]
23. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. Mehta GU; Malekzadeh P; Shelton T; White DE; Butman JA; Yang JC; Kammula US; Goff SL; Rosenberg SA; Sherry RM J Immunother; 2018 Jun; 41(5):241-247. PubMed ID: 29672342 [TBL] [Abstract][Full Text] [Related]
24. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429 [TBL] [Abstract][Full Text] [Related]
25. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. Ellebaek E; Iversen TZ; Junker N; Donia M; Engell-Noerregaard L; Met Ö; Hölmich LR; Andersen RS; Hadrup SR; Andersen MH; thor Straten P; Svane IM J Transl Med; 2012 Aug; 10():169. PubMed ID: 22909342 [TBL] [Abstract][Full Text] [Related]
26. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors. Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300 [TBL] [Abstract][Full Text] [Related]
27. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. van den Berg JH; Heemskerk B; van Rooij N; Gomez-Eerland R; Michels S; van Zon M; de Boer R; Bakker NAM; Jorritsma-Smit A; van Buuren MM; Kvistborg P; Spits H; Schotte R; Mallo H; Karger M; van der Hage JA; Wouters MWJM; Pronk LM; Geukes Foppen MH; Blank CU; Beijnen JH; Nuijen B; Schumacher TN; Haanen JBAG J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753545 [TBL] [Abstract][Full Text] [Related]
28. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? Svane IM; Verdegaal EM Cancer Immunol Immunother; 2014 Oct; 63(10):1081-91. PubMed ID: 25099366 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Dafni U; Michielin O; Lluesma SM; Tsourti Z; Polydoropoulou V; Karlis D; Besser MJ; Haanen J; Svane IM; Ohashi PS; Kammula US; Orcurto A; Zimmermann S; Trueb L; Klebanoff CA; Lotze MT; Kandalaft LE; Coukos G Ann Oncol; 2019 Dec; 30(12):1902-1913. PubMed ID: 31566658 [TBL] [Abstract][Full Text] [Related]
30. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. Turcotte S; Gros A; Hogan K; Tran E; Hinrichs CS; Wunderlich JR; Dudley ME; Rosenberg SA J Immunol; 2013 Sep; 191(5):2217-25. PubMed ID: 23904171 [TBL] [Abstract][Full Text] [Related]
31. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Chandran SS; Somerville RPT; Yang JC; Sherry RM; Klebanoff CA; Goff SL; Wunderlich JR; Danforth DN; Zlott D; Paria BC; Sabesan AC; Srivastava AK; Xi L; Pham TH; Raffeld M; White DE; Toomey MA; Rosenberg SA; Kammula US Lancet Oncol; 2017 Jun; 18(6):792-802. PubMed ID: 28395880 [TBL] [Abstract][Full Text] [Related]
32. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C; Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070 [TBL] [Abstract][Full Text] [Related]
33. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Poschke I; Lövgren T; Adamson L; Nyström M; Andersson E; Hansson J; Tell R; Masucci GV; Kiessling R Cancer Immunol Immunother; 2014 Oct; 63(10):1061-71. PubMed ID: 24993563 [TBL] [Abstract][Full Text] [Related]
34. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Pockaj BA; Sherry RM; Wei JP; Yannelli JR; Carter CS; Leitman SF; Carasquillo JA; Steinberg SM; Rosenberg SA; Yang JC Cancer; 1994 Mar; 73(6):1731-7. PubMed ID: 8156501 [TBL] [Abstract][Full Text] [Related]